214 related articles for article (PubMed ID: 30305342)
21. Integrative analysis of breast cancer profiles in TCGA by TNBC subgrouping reveals novel microRNA-specific clusters, including miR-17-92a, distinguishing basal-like 1 and basal-like 2 TNBC subtypes.
Kalecky K; Modisette R; Pena S; Cho YR; Taube J
BMC Cancer; 2020 Feb; 20(1):141. PubMed ID: 32085745
[TBL] [Abstract][Full Text] [Related]
22. Refinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection.
Lehmann BD; Jovanović B; Chen X; Estrada MV; Johnson KN; Shyr Y; Moses HL; Sanders ME; Pietenpol JA
PLoS One; 2016; 11(6):e0157368. PubMed ID: 27310713
[TBL] [Abstract][Full Text] [Related]
23. Biology and Management of Patients With Triple-Negative Breast Cancer.
Sharma P
Oncologist; 2016 Sep; 21(9):1050-62. PubMed ID: 27401886
[TBL] [Abstract][Full Text] [Related]
24. Biomarkers of DNA Repair and Related Pathways: Significance of Treatment in Triple-Negative Breast Cancer.
Guo W; Lin L; He X; He F; Wang C; Chen N; Wang Y
Crit Rev Oncog; 2017; 22(5-6):427-437. PubMed ID: 29604922
[TBL] [Abstract][Full Text] [Related]
25. Cisplatin-resistant triple-negative breast cancer subtypes: multiple mechanisms of resistance.
Hill DP; Harper A; Malcolm J; McAndrews MS; Mockus SM; Patterson SE; Reynolds T; Baker EJ; Bult CJ; Chesler EJ; Blake JA
BMC Cancer; 2019 Nov; 19(1):1039. PubMed ID: 31684899
[TBL] [Abstract][Full Text] [Related]
26. MUC1-C integrates activation of the IFN-γ pathway with suppression of the tumor immune microenvironment in triple-negative breast cancer.
Yamashita N; Long M; Fushimi A; Yamamoto M; Hata T; Hagiwara M; Bhattacharya A; Hu Q; Wong KK; Liu S; Kufe D
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33495298
[TBL] [Abstract][Full Text] [Related]
27. Cross-species genomic and functional analyses identify a combination therapy using a CHK1 inhibitor and a ribonucleotide reductase inhibitor to treat triple-negative breast cancer.
Bennett CN; Tomlinson CC; Michalowski AM; Chu IM; Luger D; Mittereder LR; Aprelikova O; Shou J; Piwinica-Worms H; Caplen NJ; Hollingshead MG; Green JE
Breast Cancer Res; 2012 Jul; 14(4):R109. PubMed ID: 22812567
[TBL] [Abstract][Full Text] [Related]
28. Molecular subtyping and genomic profiling expand precision medicine in refractory metastatic triple-negative breast cancer: the FUTURE trial.
Jiang YZ; Liu Y; Xiao Y; Hu X; Jiang L; Zuo WJ; Ma D; Ding J; Zhu X; Zou J; Verschraegen C; Stover DG; Kaklamani V; Wang ZH; Shao ZM
Cell Res; 2021 Feb; 31(2):178-186. PubMed ID: 32719455
[TBL] [Abstract][Full Text] [Related]
29. Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer.
Telli ML; Timms KM; Reid J; Hennessy B; Mills GB; Jensen KC; Szallasi Z; Barry WT; Winer EP; Tung NM; Isakoff SJ; Ryan PD; Greene-Colozzi A; Gutin A; Sangale Z; Iliev D; Neff C; Abkevich V; Jones JT; Lanchbury JS; Hartman AR; Garber JE; Ford JM; Silver DP; Richardson AL
Clin Cancer Res; 2016 Aug; 22(15):3764-73. PubMed ID: 26957554
[TBL] [Abstract][Full Text] [Related]
30. BRCA1-IRIS inactivation overcomes paclitaxel resistance in triple negative breast cancers.
Blanchard Z; Paul BT; Craft B; ElShamy WM
Breast Cancer Res; 2015 Jan; 17(1):5. PubMed ID: 25583261
[TBL] [Abstract][Full Text] [Related]
31. Risk stratification of triple-negative breast cancer with core gene signatures associated with chemoresponse and prognosis.
Kim EK; Park AK; Ko E; Park WY; Lee KM; Noh DY; Han W
Breast Cancer Res Treat; 2019 Nov; 178(1):185-197. PubMed ID: 31342312
[TBL] [Abstract][Full Text] [Related]
32. A large collection of integrated genomically characterized patient-derived xenografts highlighting the heterogeneity of triple-negative breast cancer.
Coussy F; de Koning L; Lavigne M; Bernard V; Ouine B; Boulai A; El Botty R; Dahmani A; Montaudon E; Assayag F; Morisset L; Huguet L; Sourd L; Painsec P; Callens C; Chateau-Joubert S; Servely JL; Larcher T; Reyes C; Girard E; Pierron G; Laurent C; Vacher S; Baulande S; Melaabi S; Vincent-Salomon A; Gentien D; Dieras V; Bieche I; Marangoni E
Int J Cancer; 2019 Oct; 145(7):1902-1912. PubMed ID: 30859564
[TBL] [Abstract][Full Text] [Related]
33. Integrative exploration of genomic profiles for triple negative breast cancer identifies potential drug targets.
Wang X; Guda C
Medicine (Baltimore); 2016 Jul; 95(30):e4321. PubMed ID: 27472710
[TBL] [Abstract][Full Text] [Related]
34. BRCA Mutational Status is a Promising Predictive Biomarker for Platinum- based Chemotherapy in Triple-Negative Breast Cancer.
Tazzite A; Jouhadi H; Benider A; Nadifi S
Curr Drug Targets; 2020; 21(10):962-973. PubMed ID: 32013831
[TBL] [Abstract][Full Text] [Related]
35. Gene regulatory pattern analysis reveals essential role of core transcriptional factors' activation in triple-negative breast cancer.
Min L; Zhang C; Qu L; Huang J; Jiang L; Liu J; Pinello L; Yuan GC; Shou C
Oncotarget; 2017 Mar; 8(13):21938-21953. PubMed ID: 28423538
[TBL] [Abstract][Full Text] [Related]
36. MicroRNA profiling identifies Forkhead box transcription factor M1 (FOXM1) regulated miR-186 and miR-200b alterations in triple negative breast cancer.
Hamurcu Z; Sener EF; Taheri S; Nalbantoglu U; Kokcu ND; Tahtasakal R; Cınar V; Guler A; Ozkul Y; Dönmez-Altuntas H; Ozpolat B
Cell Signal; 2021 Jul; 83():109979. PubMed ID: 33744419
[TBL] [Abstract][Full Text] [Related]
37. Integrated genomics and functional validation identifies malignant cell specific dependencies in triple negative breast cancer.
Patel N; Weekes D; Drosopoulos K; Gazinska P; Noel E; Rashid M; Mirza H; Quist J; Brasó-Maristany F; Mathew S; Ferro R; Pereira AM; Prince C; Noor F; Francesch-Domenech E; Marlow R; de Rinaldis E; Grigoriadis A; Linardopoulos S; Marra P; Tutt ANJ
Nat Commun; 2018 Mar; 9(1):1044. PubMed ID: 29535384
[TBL] [Abstract][Full Text] [Related]
38. Genomic insights into triple-negative and HER2-positive breast cancers using isogenic model systems.
Mudvari P; Ohshiro K; Nair V; Horvath A; Kumar R
PLoS One; 2013; 8(9):e74993. PubMed ID: 24086418
[TBL] [Abstract][Full Text] [Related]
39. HMGA1 promotes breast cancer angiogenesis supporting the stability, nuclear localization and transcriptional activity of FOXM1.
Zanin R; Pegoraro S; Ros G; Ciani Y; Piazza S; Bossi F; Bulla R; Zennaro C; Tonon F; Lazarevic D; Stupka E; Sgarra R; Manfioletti G
J Exp Clin Cancer Res; 2019 Jul; 38(1):313. PubMed ID: 31311575
[TBL] [Abstract][Full Text] [Related]
40. Landscape analysis of adjacent gene rearrangements reveals BCL2L14-ETV6 gene fusions in more aggressive triple-negative breast cancer.
Lee S; Hu Y; Loo SK; Tan Y; Bhargava R; Lewis MT; Wang XS
Proc Natl Acad Sci U S A; 2020 May; 117(18):9912-9921. PubMed ID: 32321829
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
